|
|
 |
|
Viewing report
|
|
|
|
Market Dynamics 2001: Hormonals
Datamonitor, Feb 2001
One of the causes of prostate and breast cancers is an imbalance in testosterone and estrogen (male and female hormones) levels in the body. Controlling the levels of hormones through the use of hormonal agents thus plays a key role in treating patients affected by these cancers. As with other cancer types, if treated early, the chance of survival is high. However, since prostate and breast cancer are two of the most prevalent cancers, affecting some 1.7 million males and 2.3 million females across seven major markets in 2000, respectively, these cancers remain leading causes of death. As a result of this large patient population, the cancer hormonals market should be an attractive target for pharmaceutical companies to pursue in terms of R&D. However, the market remains stagnant, with a distinct lack of competition with different classes dominated by few drugs. Market Dynamics 2001: Hormonals report examines the current hormonal products and the key factors that have and will have an impact on the competitive dynamics of the whole market. These factors are then analyzed in subsequent sections to forecast the sales revenues of hormonals products over the period 2001-2008.
Customers who bought this item also bought
Drugs of Tomorrow 2000: Prostate Cancer - Hormonals and Beyond
Market Dynamics 2001: Cytotoxics
Market Dynamics 2001: Anti-Cancer Innovatives Series
Commercial Perspectives: Anti-Hormonals - Tamoxifen to be Obsolete by 2010?
Market Dynamics 2001: Bacterial Infections
Market Dynamics 2001: Anti-emetics
Cancer Therapeutics 2006: Market Dynamics and R&D Trends
Market Dynamics 2001: Anticoagulants - The Advent of a New Generation of Agents
|
|
|
|
